Literature DB >> 17434719

Adjuvant chemoradiation for gastric cancer: experience in the Chinese population.

W K Tsang1, S F Leung, S K W Chiu, W W K Yeung, E K W Ng, W Yeo, K C Lam, P W Y Chiu, B B Y Ma, W H Kwan, A T C Chan.   

Abstract

AIMS: The role of adjuvant chemoradiation for gastric cancer after curative R0 gastrectomy was first established by the US Intergroup 0116 study. Although confirmatory studies are in progress, few data are available regarding its application to the Chinese population. We describe our radiotherapy technique and report the treatment results in Hong Kong.
MATERIALS AND METHODS: This was a single centre retrospective study on 63 Chinese patients who underwent adjuvant chemoradiation for gastric adenocarcinoma between June 2000 and December 2004. The treatment protocol was based on that of the Intergroup study. Computed tomography planned anteroposterior opposing field arrangement and treatment under breath hold at deep inspiration position were adopted.
RESULTS: In total, 63 patients, mean age 50 years, with gastric cancer stage IB to limited metastatic IV disease were analysed. The median follow-up time was 27.2 months. The relapse-free survival and overall survival at 3 years were 50 and 54%, respectively. The recurrence pattern was dominated by distant failure and only one patient developed isolated locoregional recurrence. Of the 10 patients who had positive microscopic surgical margins after surgery, seven had recurred and died. On multivariate analysis, margin status was the only significant prognosticator for survival. Thirty per cent of patients experienced grade 3 or above acute toxicity (24% haematological, 14% gastrointestinal) and one patient died of neutropenic sepsis. There was one case of grade 3 late toxicity.
CONCLUSIONS: The outcome after adjuvant chemoradiation for gastric cancer seemed to be favourable, with manageable toxicities, in the Chinese population. Locoregional failure was uncommon. Patients with microscopic surgical margin involvement had a very high failure rate despite adjuvant chemoradiation.

Entities:  

Mesh:

Year:  2007        PMID: 17434719     DOI: 10.1016/j.clon.2007.03.004

Source DB:  PubMed          Journal:  Clin Oncol (R Coll Radiol)        ISSN: 0936-6555            Impact factor:   4.126


  5 in total

1.  Adjuvant chemoradiotherapy versus adjuvant chemotherapy for R1 resected gastric cancer: a retrospective cohort study.

Authors:  Meng-Long Zhou; Gui-Chao Li; Wang Yang; Wei-Juan Deng; Ran Hu; Yan Wang; Zi-Wen Long; Xiao-Wen Liu; Ya-Nong Wang; Zhen Zhang
Journal:  Br J Radiol       Date:  2018-06-27       Impact factor: 3.039

Review 2.  Recent advances in chemotherapy and chemoradiotherapy for gastrointestinal tract cancers: adjuvant chemoradiotherapy for gastric cancer.

Authors:  Yukinori Kurokawa; Mitsuru Sasako
Journal:  Int J Clin Oncol       Date:  2008-12-18       Impact factor: 3.402

3.  Postoperative chemoradiation for resected gastric cancer--is the Macdonald Regimen Tolerable? a retrospective multi-institutional study.

Authors:  Yulia Kundel; Ofer Purim; Efraim Idelevich; Konstantin Lavrenkov; Sofia Man; Svetlana Kovel; Natalia Karminsky; Raphael M Pfeffer; Bella Nisenbaum; Eyal Fenig; Aaron Sulkes; Baruch Brenner
Journal:  Radiat Oncol       Date:  2011-09-29       Impact factor: 3.481

4.  Adjuvant chemoradiotherapy after d2-lymphadenectomy for gastric cancer: the role of n-ratio in patient selection. results of a single cancer center.

Authors:  Wilson L Costa; Felipe J F Coimbra; Ricardo C Fogaroli; Héber S C Ribeiro; Alessandro L Diniz; Maria Dirlei F L Begnami; Celso A L Mello; Marcelo F Fanelli; Milton J B Silva; José Humberto Fregnani; André L Montagnini
Journal:  Radiat Oncol       Date:  2012-10-15       Impact factor: 3.481

Review 5.  Postoperative chemoradiotherapy versus chemotherapy for R0 resected gastric cancer with D2 lymph node dissection: an up-to-date meta-analysis.

Authors:  Meng-Long Zhou; Mei Kang; Gui-Chao Li; Xiao-Mao Guo; Zhen Zhang
Journal:  World J Surg Oncol       Date:  2016-08-08       Impact factor: 2.754

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.